Evidence map›Paper›PMID 37174636›Full record

ReviewCells2023

The Role of Ryanodine Receptors in Regulating Neuronal Activity and Its Connection to the Development of Alzheimer's Disease.

Giuseppe Chiantia, Enis Hidisoglu, Andrea Marcantoni

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. CRISPR/Cas9-mediatedFrontiers in physiology · 2026
    Article
  2. Article
  3. Inter-Organellar CaCells · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Amyloid β-Oligomers Inhibit the Nuclear CaAntioxidants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Giuseppe ChiantiaDepartment of Neuroscience, University of Turin, 10125 Turin, Italy.ORCID 0000-0001-7971-4994
Enis HidisogluDepartment of Drug and Science Technology, University of Torino, Corso Raffaello 30, 10125 Torino, Italy.ORCID 0000-0002-1729-1209
Andrea MarcantoniDepartment of Drug and Science Technology, University of Torino, Corso Raffaello 30, 10125 Torino, Italy.ORCID 0000-0001-5825-7827
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research into the early impacts of Alzheimer's disease (AD) on synapse function is one of the most promising approaches to finding a treatment. In this context, we have recently demonstrated that the Abeta42 peptide, which builds up in the brain during the processing of the amyloid precursor protein (APP), targets the ryanodine receptors (RyRs) of mouse hippocampal neurons and potentiates calcium (Ca

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCalciumMiceNeuronsRyanodine Receptor Calcium Release ChannelAmyloid beta-Protein PrecursorCalciumRyanodine Receptor Calcium Release ChannelAlzheimer’s diseasecalcium dysregulationneuronal excitabilityryanodine receptorssynaptic function

Identifiers

PMID37174636
PMCPMC10177020
OpenAlexW4366991484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.